Reductive effect of lonazolac on lung metastasis formation in mice.
The purpose of this study was to determine the antimetastatic potential of lonazolac. Intravenous inoculation of Lewis lung carcinoma (LLC) or melanoma B-16 (B-16) cells induced macroscopically detectable lung metastases on day 15 after inoculation. After pre- and post-treatment with lonazolac-Ca at oral doses of 1, 25, and 50 mg/kg, the numbers of animals with lung metastases and the score of metastases significantly decreased. Lonazolac-Ca had similar effects also on the formation of spontaneous lung metastases. After treatment with lonazolac-Ca at oral daily doses of 1, 25, and 50 mg/kg during 8 days (LLC) or 10 days (B-16) after inoculation of the tumor cells, the number of animals developing spontaneous lung metastases and the score of metastases also decreased. Intravenous injection of lonazolac natrium was effective in protecting the mice inoculated with 1 X 10(6) melanoma B-16 cells against acute pulmonary embolic death.
Mamytbeková
A
A
Research Institute for Pharmacy and Biochemistry, Prague, Czechoslovakia.
Hájícek
J
J
Grimová
J
J
Rezábek
K
K
D000818:Animals; D000970:Antineoplastic Agents; D008175:Lung Neoplasms / Q000517:prevention & control / Q000556:secondary*; D008297:Male; D008545:Melanoma / Q000517:prevention & control / Q000556:secondary*; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D009360:Neoplastic Cells, Circulating / Q000187:drug effects*; D011655:Pulmonary Embolism / Q000517:prevention & control; D011720:Pyrazoles / Q000494:pharmacology*
D000970:Antineoplastic Agents; D011720:Pyrazoles; C017472:lonazolac